Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in the Jefferies London Healthcare Conference on November 14-16, 2023.

Archived webcasts from investor conferences are available on the events section of the company’s investor relations website.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS). To learn more, visit www.sprucebio.com and follow us on Twitter/X @Spruce_Bio, LinkedIn, Facebook and YouTube.

Media Contact Will Zasadny Evoke Canale (619) 961-8848 will.zasadny@evokegroup.com media@sprucebio.com

Investors Samir Gharib President and CFO Spruce Biosciences investors@sprucebio.com

Spruce Biosciences (NASDAQ:SPRB)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024 Click aqui para mais gráficos Spruce Biosciences.
Spruce Biosciences (NASDAQ:SPRB)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024 Click aqui para mais gráficos Spruce Biosciences.